Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Personalized statin therapy: Targeting metabolic processes to modulate the therapeutic and adverse effects of statins.
Heliyon
January 2025
Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, Xinjiang, 830046, China.
Statins are widely used for treating lipid disorders and cardiovascular diseases. However, the therapeutic efficiency and adverse effects of statins vary among different patients, which numerous clinical and epidemiological studies have attributed to genetic polymorphisms in statin-metabolizing enzymes and transport proteins. The metabolic processes of statins are relatively complex, involving spontaneous or enzyme-catalyzed interconversion between more toxic lactone metabolites and active acid forms in the liver and bloodstream, influenced by multiple factors, including the expression levels of many metabolic enzymes and transporters.
View Article and Find Full Text PDFHistorical Control Data of Spontaneous Lesions of Laboratory New Zealand White and Dutch Belted Rabbits () Used in Toxicity Studies.
Toxicol Pathol
January 2025
Charles River Laboratories Edinburgh Ltd, Elphinstone Research Centre, Tranent, UK.
A retrospective study was performed to determine the incidences of spontaneous findings in control laboratory New Zealand White (NZW) and Dutch Belted (DB) rabbits. Terminal body and organ weights data were also collected. A total of 2170 NZW (526 males/1644 females), 100 DB rabbits (50 animals per sex), aged 4- to 7-month-old were obtained from 158 non-clinical studies evaluated between 2013 and 2022.
View Article and Find Full Text PDFAdvances in liver organoids: replicating hepatic complexity for toxicity assessment and disease modeling.
Stem Cell Res Ther
January 2025
Organoid Innovation Center, Suzhou Institute of Nanotech and Nano-bionics, Chinese Academy of Sciences, 398 Ruoshui Rd, Suzhou, Jiangsu, 215123, China.
The lack of in vivo accurate human liver models hinders the investigation of liver-related diseases, injuries, and drug-related toxicity, posing challenges for both basic research and clinical applications. Traditional cellular and animal models, while widely used, have significant limitations in replicating the liver's complex responses to various stressors. Liver organoids derived from human pluripotent stem cells, adult stem cells primary cells, or tissues can mimic diverse liver cell types, major physiological functions, and architectural features.
View Article and Find Full Text PDFPhytochemical profile of Taxus globosa Schltdl. and its anxiolytic, antinociceptive, and toxicological evaluation in mice.
J Ethnopharmacol
January 2025
Posgrado en Botánica, Colegio Postgraduados Campus Montecillo Km. 36.5 Carretera México-Texcoco C.P. Montecillo, 56264, Texcoco Estado de México, México. Electronic address:
Ethnopharmacological Relevance: Taxus globosa Schltdl. (Taxaceae) is commonly named "Tejo mexicano". It's a Mexican plant known in folk medicine as a remedy for pain such as stomachache and headache, arthritis, gout, and other inflammatory conditions.
View Article and Find Full Text PDFSafety of ceftobiprole in patients with impaired renal, hepatic or immune function: a multinational retrospective hospital chart review (RETRACE study).
Int J Antimicrob Agents
January 2025
Department of Precision Medicine, University of Campania "Luigi Vanvitelli"; Unit of Internal Medicine and Transplants, AORN Ospedali dei Colli, Ospedale V. Monaldi, Piazzale Ettore Ruggieri, 80131, Napoli, Italy. Electronic address:
Ceftobiprole, an advanced-generation cephalosporin with broad bactericidal activity, is approved for community-acquired and hospital-acquired pneumonia (excluding ventilator-associated pneumonia). We aimed to evaluate, in a real-world setting, the safety profile of ceftobiprole in patients with risk conditions (severe renal impairment, hepatic impairment, and immunocompromised status), groups excluded from clinical trials. In this retrospective study (NCT04170309), 396 consecutive charts of patients treated with ceftobiprole during 2016-2022 in 15 centers in France, Italy, and Spain were analyzed: 62 had severe renal impairment, 51 had hepatic impairment, 120 were immunocompromised, and 203 had no predefined risk condition (controls).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!